Sernova Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jonathan N. Rigby
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The Stiller Centre London ON United Kingdom N6G 4X8
- IPO Date
- Feb 21, 2007
- CIK
- 0001491434
- Website
- sernova.com
- Similar Companies
- Business
- Sernova Biotherapeutics Inc. (TSX: SVA, OTCQB: SEOVF), formerly Sernova Corp., operates as a clinical-stage biotechnology company focused on regenerative medicine therapeutics for chronic diseases including type 1 diabetes (T1D), thyroid disorders and hemophilia A; the company develops its proprietary implantable Cell Pouch bio-hybrid organ system, which supports vascularized tissue chambers for the engraftment, longevity and function of transplanted therapeutic cells such as human donor islet cells or stem cell-derived islet-like clusters developed in collaboration with Evotec SE, enabling physiologic secretion of insulin, hormones, proteins and factors to restore natural organ functions while providing immune protection and retrievability. Founded in 2006 and headquartered at 700 Collip Circle, Suite 114, London, Ontario, Canada, Sernova conducts clinical operations primarily in Canada and pursues global partnerships for its platform applicable to insulin-dependent diabetes, hypothyroidism and blood disorders. Recent developments include a name change to Sernova Biotherapeutics Inc. in February 2025; a CAD $13.8 million debt-to-equity conversion in October 2025 eliminating legacy financing overhang; closing of the first tranche of a private placement equity financing in November 2025 to support general operations and launch of Cohort C in its ongoing Phase 1/2 clinical trial incorporating tegoprubart from Eledon Pharmaceuticals under a July 2025 collaboration; a $4 million loan secured in April 2025 to advance clinical plans; appointment of John L. Brooks III as board chair in September 2025 and formation of a clinical advisory board in May 2025; alongside positive interim data from its T1D trial reported in May 2025.
Sernova Biotherapeutics Announces Closing of Recently Approved Financings
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
Sernova Biotherapeutics Announces Warrant Amendments
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
Sernova Appoints Jonathan Rigby as Interim Chair
Chair of Sernova Biotherapeutics Resigns
Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes
Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes
Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans
Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes
Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D
Sernova Biotherapeutics Secures $1 Million Convertible Debt Financing
Sernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism
Sernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism
Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025